Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
331 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015’, provides an overview of the Relapsed Acute Myeloid Leukemia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Acute Myeloid Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsed Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsed Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Relapsed Acute Myeloid Leukemia Overview 9 Therapeutics Development 10 Pipeline Products for Relapsed Acute Myeloid Leukemia - Overview 10 Pipeline Products for Relapsed Acute Myeloid Leukemia - Comparative Analysis 11 Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies 12 Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 17 Relapsed Acute Myeloid Leukemia - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Relapsed Acute Myeloid Leukemia - Products under Development by Companies 21 Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 25 Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 26 4SC AG 26 AbbVie Inc. 27 Actinium Pharmaceuticals, Inc. 28 Agios Pharmaceuticals, Inc. 29 Amgen Inc. 30 Array BioPharma Inc. 31 Astellas Pharma Inc. 32 Astex Pharmaceuticals, Inc. 33 AstraZeneca PLC 34 AVEO Pharmaceuticals, Inc. 35 Boehringer Ingelheim GmbH 36 Bristol-Myers Squibb Company 37 Calithera Biosciences, Inc. 38 Celgene Corporation 39 Conkwest, Inc. 40 Cornerstone Pharmaceuticals, Inc. 41 CTI BioPharma Corp. 42 Daiichi Sankyo Company, Limited 43 Eisai Co., Ltd. 44 EpiZyme, Inc. 45 Exelixis, Inc. 46 F. Hoffmann-La Roche Ltd. 47 Fujifilm Corporation 48 GlaxoSmithKline plc 49 Igenica Biotherapeutics, Inc. 50 Incyte Corporation 51 Jiangsu Hansoh Pharmaceutical Co., Ltd. 52 JW Pharmaceutical Corporation 53 Karyopharm Therapeutics, Inc. 54 Kyowa Hakko Kirin Co., Ltd. 55 Les Laboratoires Servier SAS 56 MacroGenics, Inc. 57 Merck & Co., Inc. 58 Millennium Pharmaceuticals, Inc. 59 Novartis AG 60 Oxford BioTherapeutics Ltd 61 Plexxikon Inc. 62 Polaris Pharmaceuticals, Inc. 63 Seattle Genetics, Inc. 64 Sunesis Pharmaceuticals, Inc. 65 Synta Pharmaceuticals Corp. 66 Tolero Pharmaceuticals, Inc. 67 Verastem, Inc. 68 Relapsed Acute Myeloid Leukemia - Therapeutics Assessment 69 Assessment by Monotherapy Products 69 Assessment by Combination Products 70 Assessment by Target 71 Assessment by Mechanism of Action 75 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 4SC-202 - Drug Profile 82 AG-120 - Drug Profile 84 AG-221 - Drug Profile 86 alvocidib hydrochloride - Drug Profile 89 AMG-232 - Drug Profile 90 AT-9283 - Drug Profile 91 BI-836858 - Drug Profile 93 binimetinib - Drug Profile 94 bortezomib - Drug Profile 99 brentuximab vedotin - Drug Profile 104 cabozantinib s-malate - Drug Profile 109 cafusertib hydrochloride - Drug Profile 112 CB-839 - Drug Profile 113 Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile 114 Cell Therapy to Target CD33 for Acute Myeloid Leukemia - Drug Profile 115 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 116 CPI-613 - Drug Profile 117 crenolanib besylate - Drug Profile 119 CST-101 - Drug Profile 121 CWP-291 - Drug Profile 123 DFP-10917 - Drug Profile 125 DS-3032 - Drug Profile 126 elesclomol - Drug Profile 127 EPZ-5676 - Drug Profile 129 erlotinib hydrochloride - Drug Profile 131 FF-10501 - Drug Profile 134 ficlatuzumab - Drug Profile 135 FLX-925 - Drug Profile 137 gilteritinib fumarate - Drug Profile 138 GO-2032c - Drug Profile 139 GSK-2879552 - Drug Profile 140 GSK-525762 - Drug Profile 141 huCART19 - Drug Profile 142 IGN-523 - Drug Profile 143 ilorasertib - Drug Profile 144 imatinib mesylate - Drug Profile 146 indisulam - Drug Profile 148 Iomab-B - Drug Profile 149 KHK-2823 - Drug Profile 151 lenalidomide - Drug Profile 152 LGH-447 - Drug Profile 156 MGD-006 - Drug Profile 157 MK-2206 - Drug Profile 158 OX-001 - Drug Profile 161 pegargiminase - Drug Profile 162 PLX-3397 - Drug Profile 165 quizartinib dihydrochloride - Drug Profile 167 RG-7775 - Drug Profile 170 ruxolitinib phosphate - Drug Profile 171 S-055746 - Drug Profile 176 selinexor - Drug Profile 177 selumetinib sulfate - Drug Profile 181 Small Molecules to Inhibit MDM2 for Oncology - Drug Profile 184 TAK-659 - Drug Profile 185 TEN-010 - Drug Profile 186 tigecycline - Drug Profile 187 tosedostat - Drug Profile 188 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 190 ulocuplumab - Drug Profile 192 venetoclax - Drug Profile 194 vorinostat - Drug Profile 197 vosaroxin - Drug Profile 201 VS-4718 - Drug Profile 203 Relapsed Acute Myeloid Leukemia - Recent Pipeline Updates 204 Relapsed Acute Myeloid Leukemia - Dormant Projects 316 Relapsed Acute Myeloid Leukemia - Discontinued Products 317 Relapsed Acute Myeloid Leukemia - Product Development Milestones 318 Featured News & Press Releases 318 Appendix 326 Methodology 326 Coverage 326 Secondary Research 326 Primary Research 326 Expert Panel Validation 326 Contact Us 326 Disclaimer 327
List of Tables Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2015 14 Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Development by Companies, H1 2015 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2015 29 Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2015 30 Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2015 31 Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32 Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 33 Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2015 34 Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2015 35 Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2015 36 Relapsed Acute Myeloid Leukemia - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37 Relapsed Acute Myeloid Leukemia - Pipeline by AstraZeneca PLC, H1 2015 38 Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 39 Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2015 40 Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2015 41 Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2015 42 Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2015 43 Relapsed Acute Myeloid Leukemia - Pipeline by Conkwest, Inc., H1 2015 44 Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 45 Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2015 46 Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 47 Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2015 48 Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2015 49 Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2015 50 Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 51 Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2015 52 Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline plc, H1 2015 53 Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2015 54 Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2015 55 Relapsed Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 56 Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2015 57 Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 58 Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 59 Relapsed Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2015 60 Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2015 61 Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2015 62 Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 63 Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2015 64 Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2015 65 Relapsed Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2015 66 Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 67 Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2015 68 Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 69 Relapsed Acute Myeloid Leukemia - Pipeline by Synta Pharmaceuticals Corp., H1 2015 70 Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 71 Relapsed Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2015 72 Assessment by Monotherapy Products, H1 2015 73 Assessment by Combination Products, H1 2015 74 Number of Products by Stage and Target, H1 2015 76 Number of Products by Stage and Mechanism of Action, H1 2015 80 Number of Products by Stage and Route of Administration, H1 2015 83 Number of Products by Stage and Molecule Type, H1 2015 85 Relapsed Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 208 Relapsed Acute Myeloid Leukemia - Dormant Projects, H1 2015 320 Relapsed Acute Myeloid Leukemia - Discontinued Products, H1 2015 321
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
